|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2500106956 |
|
最近更新日期: Date of Last Refreshed on: |
2025-07-31 21:17:55 |
|
注册时间: Date of Registration: |
2025-07-31 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
胃癌血清早期诊断标志物circ7991等联合检测的临床价值研究 |
|
Public title: |
Combined detection of serum circ7991 and other markers for early diagnosis of gastric cancer and its mechanism of action. |
|
注册题目简写: |
胃癌血清早期诊断标志物的临床价值研究 |
|
English Acronym: |
Study on the clinical value of early diagnosis markers of gastric cancer serum |
|
研究课题的正式科学名称: |
胃癌血清早期诊断标志物circ7991等联合检测的临床价值研究 |
|
Scientific title: |
Combined detection of serum circ7991 and other markers for early diagnosis of gastric cancer and its mechanism of action. |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
张宇 |
研究负责人: |
张宇 |
|
Applicant: |
Yu Zhang |
Study leader: |
Yu Zhang |
|
申请注册联系人电话: Applicant telephone: |
+86 188 5140 0030 |
研究负责人电话: Study leader's telephone: |
+86 188 5140 0030 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
zhangyu001100@sina.com |
研究负责人电子邮件: Study leader's E-mail: |
zhangyu001100@sina.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
江苏省南京市中山路321号 |
研究负责人通讯地址: |
江苏省南京市中山路321号 |
|
Applicant address: |
No. 321, Zhongshan Road, Nanjing City, Jiangsu Province |
Study leader's address: |
No. 321, Zhongshan Road, Nanjing City, Jiangsu Province |
|
申请注册联系人邮政编码: Applicant postcode: |
210008 |
研究负责人邮政编码: Study leader's postcode: |
210008 |
|
申请人所在单位: |
南京大学医学院附属鼓楼医院 |
||
|
Applicant's institution: |
Drum Tower Hospital Affiliated to Nanjing University School of Medicine |
||
|
研究负责人所在单位: |
南京大学医学院附属鼓楼医院 |
||
|
Affiliation of the Leader: |
Drum Tower Hospital Affiliated to Nanjing University School of Medicine |
||
|
是否获伦理委员会批准: |
是/Yes |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
2024-704-02 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
南京大学医学院附属鼓楼医院医学伦理委员会 |
||
|
Name of the ethic committee: |
Ethics Committee of Gulou Hospital Affiliated to Nanjing University School of Medicine |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2024-11-25 00:00:00 |
||
|
伦理委员会联系人: |
陈军浩 |
||
|
Contact Name of the ethic committee: |
Junhao Chen |
||
|
伦理委员会联系地址: |
江苏省南京市中山路321号 |
||
|
Contact Address of the ethic committee: |
241 North Zhongshan Road |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 139 5179 9653 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
南京大学医学院附属鼓楼医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Drum Tower Hospital Affiliated to Nanjing University School of Medicine |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
江苏省南京市中山路321号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No. 321, Zhongshan Road, Nanjing City, Jiangsu Province |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
国家自然科学基金 |
||||||||||||||||||||||
|
Source(s) of funding: |
National Natural Science Foundation |
||||||||||||||||||||||
|
Target disease: |
Gastric cancer |
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
诊断试验 |
||||||||||||||||||||||
|
Study type: |
Diagnostic test |
||||||||||||||||||||||
|
研究所处阶段: |
诊断试验新技术临床试验 | ||||||||||||||||||||||
|
Study phase: |
Diagnostic New Technique Clincal Study |
||||||||||||||||||||||
|
研究设计: |
诊断试验诊断准确性 |
||||||||||||||||||||||
|
Study design: |
Diagnostic test for accuracy |
||||||||||||||||||||||
|
研究目的: |
明确基于血清 circRNAs、eccDNAs等联合检测在胃癌早期诊断中的临床价值。 |
||||||||||||||||||||||
|
Objectives of Study: |
Clarify the clinical value of serum circRNAs, eccDNAs and other combined detection in the early diagnosis of gastric cancer. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
研究人员在医院病历系统查询、筛选(根据纳入、排除标准)并记录所有适合入组人群。筛选合格的胃癌患者,留取患者术前血常规/生化常规检查后的剩余标本以备实验,在患者根治性术后、手术室病理科获取胃癌组织及配对癌旁组织标本。筛选合格的胃炎患者,在检验科取血液检验后剩余标本,进行血清分离,冻存,以备实验。筛选合格的健康人群,在检验科取血液检验后剩余标本,进行血清分离,冻存,以备实验。 |
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
Researchers will screen and identify all eligible participants by reviewing the hospital medical record system in accordance with the inclusion and exclusion criteria, and record the relevant information. For eligible gastric cancer patients, residual blood samples from routine preoperative hematological/biochemical tests will be collected for future experiments. Gastric cancer tissues and matched adjacent non-cancerous tissues will be obtained from the pathology department after radical surgery. For eligible gastritis patients, residual blood specimens from routine laboratory tests will be collected in the clinical laboratory, followed by serum separation and cryopreservation for future experiments. For eligible healthy individuals, residual blood specimens from routine laboratory tests will also be collected, and serum will be separated and cryopreserved for future experiments. |
||||||||||||||||||||||
|
纳入标准: |
1、胃癌患者的合格受试者必须符合以下所有标准: (1)经病理证实为胃癌 (2)术前未接受任何抗癌治疗(包括放化疗、免疫治疗、靶向治疗等) (3)具有完整的临床、病理资料 (4)无既往胃癌病史及治疗史 2、胃炎患者合格受试者必须符合以下所有标准:(1)胃镜检查确诊明确经胃镜检查诊断为慢性胃炎(如慢性浅表性胃炎、慢性萎缩性胃炎);(2)既往无肿瘤病史 (3)具有完整的临床资料 3、健康人的合格受试者必须符合以下所有标准: (1)体检证实无疾病 (2)既往无肿瘤病史 (3)具有完整的临床资料 |
||||||||||||||||||||||
|
Inclusion criteria |
Eligible gastric cancer patients must meet all of the following criteria: (1) Histopathologically confirmed diagnosis of gastric cancer (2) No prior anticancer treatment before surgery (including chemotherapy, radiotherapy, immunotherapy, or targeted therapy) (3) Complete clinical and pathological data available (4) No history of gastric cancer or prior related treatment Eligible gastritis patients must meet all of the following criteria: (1) Diagnosis of chronic gastritis confirmed by endoscopy (e.g., chronic superficial gastritis, chronic atrophic gastritis) (2) No prior history of malignancy (3) Complete clinical data available Eligible healthy controls must meet all of the following criteria: (1) No evidence of disease confirmed by physical examination (2) No prior history of malignancy (3) Complete clinical data available |
||||||||||||||||||||||
|
排除标准: |
(1)术前接受放化疗或免疫治疗或靶向治疗 (2)临床信息缺失 (3)既往患有其他恶性肿瘤 |
||||||||||||||||||||||
|
Exclusion criteria: |
(1) Preoperative chemotherapy or immunotherapy or targeted therapy. (2) Lack of clinical information. (3) Suffering from other malignant tumors in the past. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2024-12-01 00:00:00至 To 2027-12-01 00:00:00 |
征募观察对象时间: Recruiting time: |
从From 2025-08-01 00:00:00 至 To 2026-02-01 00:00:00 |
|
诊断试验: Diagnostic Tests: |
|
||||||||||||||||||||||||||||
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
无 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
None |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
|
|
Blinding: |
|
是否共享原始数据: IPD sharing |
Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
文章发表后半年共享原始数据,上传国家生物信息中心 (https://ngdc.cncb.ac.cn/gsub/) |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
The original data is shared after the article is published half year, and uploaded to China National Center for Bioinformation (https://ngdc.cncb.ac.cn/gsub/). |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
病例记录表 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Case Record Form, CRF |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |